ResMed: Waking Up To Sleep Disorders
Long viewed as simply annoying habits, sleep disordered breathing (SDB) problems like snoring are, in fact, often symptoms of more severe conditions, most commonly obstructive sleep apnea (OSA). New clinical evidence is confirming the theories of early sleep medicine physicians that, in addition to causing snoring, headaches and excessive daytime sleepiness, OSA leads to severe cerebro- and cardiovascular complications, including hypertension, stroke, heart attack and sudden cardiac death. Studies are also revealing that SDB problems are extremely widespread, afflicting an estimated 40 million Americans, yet only a small percentage of those are diagnosed and treated. Very few patients are ever cured because the traditional surgical procedures that can eliminate OSA are extremely traumatic and often don't work. ResMed is fighting a two-tiered battle in attempting to develop and market devices to effectively treat OSA: first is getting patients to acknowledge and physicians to diagnose and treat this condition, and second is designing a device that is sufficiently patient-friendly to overcome what has been the Achilles heel of OSA treatment: poor patient compliance.
You may also be interested in...
Sleep Apnea Devices: The Changing Of The Guard
The current specialty-dominated care paradigm for sleep apnea can't scale-up to meet the demands of an enormous and serious chronic disease. New companies help move diagnosis and treatment to the physicians that see patients first.
The Shifting Sands of Sleep Apnea
Lack of sleep is bad in its own right, but now the knowledge that obstructive sleep apnea is a risk factor for and even a possible cause of heart disease adds urgency to what the medical community has until recently viewed as a quality of life problem. However, the existing infrastructure for diagnosing and treating OSA can neither handle the current demand nor the expected influx of new patients coming in from the cardiology community. New companies hope to fill gaps in diagnosis and therapy, but they face all the challenges of establishing technological and business approaches in an evolving field, with the need to change practice patterns, educate patients and multiple groups of physicians, and win the buy-in of payers.
The Pacemaker's Continuing Evolution: St. Jude Looks at New Apnea Therapy
The pacemaker is the ancient warhorse of the cardiac rhythm management business--45 years old and still ticking. One reason: companies keep improving and finding new uses for it. Along with treating arrhythmias, the major CRM companies have adapted pacemakers to become part of an increasingly successful device-oriented approach to treating congestive heart failure. And now St. Jude Medical is the first CRM company to begin a clinical trial investigating whether pacemakers may be an effective treatment for sleep apnea.